Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. - Wikidata - awgldk - TriplyDB

Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.

Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.

http://www.wikidata.org/entity/Q38920844

about

Tuberculosis and HIV co-infection Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America Integrated therapy for HIV and tuberculosis Current diagnosis and management of peripheral tuberculous lymphadenitis HIV & immune reconstitution inflammatory syndrome (IRIS)Diagnosis & treatment of tuberculosis in HIV co-infected patients.CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings Treatment outcomes of patients co-infected with tuberculosis and HIV at Chiang Mai University Hospital, Thailand Hospital days attributable to immune reconstitution inflammatory syndrome in persons living with HIV before and after the 2012 DHHS HIV guidelines.Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand.TB-IRIS: Proteomic analysis of in vitro PBMC responses to Mycobacterium tuberculosis and response modulation by dexamethasone Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique.d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS.AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome HIV-Associated Tuberculosis.Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART.Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma.Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction.Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections.Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras Disseminated infections due to Immune Reconstitution Inflammatory Syndrome after highly active antiretroviral therapy--report of 3 cases from Nigeria.Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options.Challenges of Childhood TB/HIV Management in Malawi.Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors.Immune reconstitution inflammatory syndrome: more answers, more questions.Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164.

P2860

Q21131403-711B88A7-9740-4B0F-B54C-B6B380D0ABD4 Q21144623-9C8E77CC-F3C5-4198-8B94-C862CE648FC8 Q21521430-26E3011D-98AC-44DC-9EA6-A76A3190926A Q26749428-E9965548-25C2-482E-B8B1-238DE728F116 Q26829145-12D72D21-9E95-4E6E-B39C-D24C1F01DB77 Q26852805-FCA90D0F-BC78-4665-B6D0-E0A6214A23A2 Q26991633-6AFF7C3D-B94E-4C24-91F8-A2D229E5F4DE Q27011721-371080EE-6071-492C-8677-6A2866D97C9D Q28069032-C19BBEE2-AD72-49D1-B360-4E7D50682355 Q28474814-AE49E4D4-6556-4C52-84B4-E4AAD7286F77 Q28749315-EE1DB2FE-FEF3-4800-B844-EDE6B7F7BF72 Q30051056-8F09472F-0E5B-4D92-A0F4-4EA64B47D6C2 Q30252460-9F742F51-A8D9-4679-A8F2-71864FB7797D Q33628799-67DE4293-5062-49EF-AF59-408EE70B9EC8 Q33686938-909411AB-99A5-4D31-A634-36BCFA249D89 Q33732480-E3953394-4ECB-4328-A16C-9B8100C46E75 Q33807615-4AFE95A3-FD0F-44CA-AA56-1F95FD687DED Q33840983-E41B0725-FFAC-4A44-88E3-2BDFF3B10A9E Q33941296-AAFAE4B4-9C43-4626-A616-080FFCBFEFCF Q34083071-7CADCC84-138C-4C8C-A6E8-5AE227A19138 Q34130659-8248008A-81BF-4AAB-B914-3C49E0996D04 Q34143510-AC57D7D2-0D76-4067-BB95-069539E7FA40 Q34282914-9BF94654-6E8C-4360-A52F-0056D57D5466 Q34415055-528C6C76-E412-4CEA-8A18-1B3260FE0412 Q34477198-B8469C3B-56BE-4F4E-AAFB-9E4DD5FA68C1 Q34516548-E06BD88D-5063-45B0-AE6E-30A338C6A4CA Q34587349-4FBFFEA3-CE49-4761-95FA-31D6DC8CBAFF Q34633782-71CA41E3-C027-468C-AB27-7401717B1B28 Q34730629-9FD2DF1B-6D96-46BE-A691-45476ABCAA01 Q34746206-A338A1CB-835F-497A-95EA-2688A9A595DD Q34978950-B158870B-FD8A-4D6E-B1E3-45302C464160 Q35494596-AB0ABF34-97DD-440F-8985-28C864F6D317 Q35548345-6179679A-E3AD-4C30-A8FD-123F00564CC7 Q35622163-995C031B-1575-42B8-9C7F-D31FEAACD49B Q35656939-3C16479E-0519-4FB0-B7BC-DB1F4309B2C7 Q35799766-663D1C4E-3FB6-4FE5-B74C-F7C371744081 Q35939235-EA012F51-4BD5-4962-86D3-138709D1ACDC Q36146226-E401A4E1-ECB9-4AE1-9FC0-2556D2FE53CB Q36342114-99AF54D3-FCB4-4D6E-AF89-46F1BD5242F8 Q36368686-97BBFD14-0500-42FA-A9AA-B1F3910813DB

P2860

Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.

http://www.wikidata.org/entity/Q38920844

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Determinants of immune reconst ...... ion of antiretroviral therapy.

@en

type

label

Determinants of immune reconst ...... ion of antiretroviral therapy.

@en

prefLabel

Determinants of immune reconst ...... ion of antiretroviral therapy.

@en

P1433

Q38920844-5B84A412-EF12-4CAE-AA90-E3FD8D0EB850

P1476

Q38920844-44DC0E00-EDFF-4CDB-BE60-D305CB9F7247

P2093

Q38920844-32FA5E2C-75E7-41DE-911B-3E8C92D2A2CA

Q38920844-5E54DD65-C998-4254-9792-E29A99FFC805

Q38920844-69649C62-D936-4C12-B0D2-CFCDAFA9E45F

Q38920844-7E5674CC-DFB8-4BBD-8A50-B3C14957B378

Q38920844-899AC300-564F-4158-BF6B-ED127CC1B19B

Q38920844-AD3D66A0-FA6A-49C5-903B-7EF32AF6230D

Q38920844-C0047BA3-14AA-4500-904F-F98A5988CB3A

Q38920844-CEA5ACC6-674B-4384-AF5A-DC35FA51379B

P2860

Q38920844-1DBB69FA-9ED7-453E-9E8A-B0423263B618

Q38920844-453EB2A5-3CEA-474B-9557-D05661FE3650

Q38920844-5A4088EB-7920-42E2-92EB-9306E3A7E044

Q38920844-6472B37A-5FC6-4175-933C-A4525AC20C8E

Q38920844-83BEE587-1F9D-487A-B9C2-888C0A1F4517

Q38920844-B55D5F78-506A-46DA-9130-9FD7649C3C6C

Q38920844-C519B083-5B99-4506-8F0B-DCCD98812208

Q38920844-D3F55AA5-7334-4DB9-814C-376214700E7E

Q38920844-D4E1F219-C3E6-496C-B2B4-D27C2B26018B

Q38920844-EAAE0E57-AFE1-4E46-AD62-D584DD8AA021

P304

Q38920844-6B8C971A-D85F-41D1-AC74-58CC50D2020B

P31

Q38920844-2BAFB2BA-25E1-4BAA-926D-95C26271DD29

P356

Q38920844-679EFE32-B002-4569-9245-992CFB730D02

P407

Q38920844-B7A1C31F-08F9-4DA5-A305-EDBCC92E718B

P433

Q38920844-B342F23F-A19D-42F1-9156-967DD98C790A

P478

Q38920844-BA57746F-135E-436E-B7D7-FD749C168474

P50

Q38920844-54292A7D-4B09-4C72-AB6F-9D09823A110B

P577

Q38920844-643C9DD9-9340-4ED2-A07A-BB0089D24CD0

P5875

Q38920844-04FC2EBF-09EF-4D13-924A-64213F13283E

P698

Q38920844-32A9AC4D-3BF2-41C6-AFCA-73849D7BB569

P921

Q38920844-27C21AC2-EBEE-4B4B-A020-831A15129C8C

Q38920844-4A47A9F7-A7E4-4AFC-82D2-CF3F9973A947

Q38920844-AF61A2C8-BCBF-43CA-8CEB-AF455E8D7B52

Q38920844-CC3EE149-7BFD-4A9A-B5E7-B30043363EE4

P356

P1433

Clinical Infectious Diseases

P1476

Determinants of immune reconst ...... ion of antiretroviral therapy.

@en

P2093

Catherine Leport

http://www.w3.org/2001/XMLSchema#string

Daniel Bonnet

http://www.w3.org/2001/XMLSchema#string

David Mvondo Mvondo

http://www.w3.org/2001/XMLSchema#string

Guillaume Breton

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Vildé

http://www.w3.org/2001/XMLSchema#string

Pascale Longuet

http://www.w3.org/2001/XMLSchema#string

Xavier Duval

http://www.w3.org/2001/XMLSchema#string

Xavier Poaletti

http://www.w3.org/2001/XMLSchema#string

P2860

Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy.

Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.

Paradoxical worsening of tuberculosis in HIV-infected persons.

Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy.

Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection.

Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.

Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy

P304

1709-1712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/425742

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Candice Estellat

P577

2004-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8150072

http://www.w3.org/2001/XMLSchema#string

P698

15578375

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

antiretroviral drug